2025-523898-42-00Not yet recruitingPhase 2/3
The Surf trial
The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Apr 2026
Brief summary (registry, in English)
To determine the optimal dose and timing of intravenous ICG to achieve sufficient tumor-to background contrast in solid tumors and to evaluate whether ICG fluorescence imaging can accurately identify tumor margins during surgery.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 16 Oct 2025
- Start date
- 1 Jan 2026
- Lead sponsor
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Diseases
- Head and neck cancer, Sarcoma
- EU CT number
- 2025-523898-42-00
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid cancer who will have surgery to remove it. It tests a fluorescent dye called ICG that may show the tumor edges.
- Age
- 18 years or older
- Sex
- Women and men can both join
- Disease stage
- Solid cancer confirmed by tissue examination (for example head and neck, gut, liver and bile ducts, breast, urinary and genital organs, sarcoma). Surgery must be planned to remove all of the disease.
Main reasons for not taking part
- Known allergy to Indocyanine Green (ICG), iodine or shellfish
- Pregnant or breastfeeding
- Significant kidney problems (eGFR <50 mL/min/1.73 m²)
- Overactive thyroid or other active thyroid disease
- Any condition the investigator thinks puts the person at undue risk or disturbs the study
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to Indocyanine Green (ICG), iodine, or shellfish
- Hyperthyroidism or other active thyroid disease
- Any condition deemed by the investigator to place the patient at undue risk or interfere with study procedures
Lab values
- Significant renal impairment (eGFR <50 mL/min/1.73 m²)
Other
- Pregnant or breastfeeding
Who the study is looking for
- Age ≥18 years
- Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)
- Candidate for surgical resection with curative intent
- Ability to provide written informed consent
- Adequate organ function to undergo surgery and ICG administration
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.